Targeted anti-vascular therapies for ovarian cancer: current evidence

Abstract

Ovarian cancer presents at advanced stage in around 75% of women, and despite improvements in treatments such as chemotherapy, the 5-year survival from the disease in women diagnosed between 1996 and 1999 in England and Wales was only 36%. Over 80% of patients with advanced ovarian cancer will relapse and despite a good chance of remission from further chemotherapy, they will usually die from their disease. Sequential treatment strategies are employed to maximise quality and length of life but patients eventually become resistant to cytotoxic agents. The expansion in understanding of the molecular biology that characterises cancer cells has led to the rapid development of new agents to target important pathways but the heterogeneity of ovarian cancer biology means that there is no predominant defect. This review attempts to discuss progress to date in tackling a more general target applicable to ovary cancer—angiogenesis.

DOI: 10.1038/bjc.2012.541

Extracted Key Phrases

3 Figures and Tables

020406020132014201520162017
Citations per Year

124 Citations

Semantic Scholar estimates that this publication has 124 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@inproceedings{Hall2013TargetedAT, title={Targeted anti-vascular therapies for ovarian cancer: current evidence}, author={Michael Edward Hall and Charlie Gourley and I McNeish and Jonathan A. Ledermann and Martin Eric Gore and G. C. Jayson and Timothy J. Perren and Gordon John Sampson Rustin and Stanley B. Kaye}, booktitle={British Journal of Cancer}, year={2013} }